Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022
Burning Rock Biotech Limited (NASDAQ: BNR) has scheduled its Annual General Meeting (AGM) for September 8, 2022, at its Shanghai office. Key proposals include the ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending December 31, 2022, re-election of directors Feng Deng, Leo Li, and Licen Lisa Xu, and the adoption of the 2022 Long-term Equity Incentive Plan. The record date for shareholder participation is set for August 4, 2022. The AGM notice and 2021 Annual Report are available on the company's Investor Relations website.
- Ratification of Ernst & Young Hua Ming LLP as auditor may boost shareholder confidence.
- Re-election of experienced directors could provide stability in leadership.
- Introduction of the 2022 Long-term Equity Incentive Plan aligns management's interests with shareholders' long-term value.
- None.
GUANGZHOU, China, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on September 8, 2022 at 10:00 a.m. (local time) at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai.
The AGM will be held for the following proposals:
- To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2022 and to authorize the directors of the Company to determine the remuneration of the auditor;
- To re-elect Feng Deng, Leo Li and Licen Lisa Xu as directors of the Company;
- To approve, confirm and ratify the adoption of the 2022 Long-term Equity Incentive Plan and the grant of options thereunder, the vesting of which is tied to the Company’s future stock performances (and options granted to Mr. Han, the Company’s founder, chairman and chief executive officer, will only start to vest after the Company’s market capitalization reaches US
$4 billion ). The 2022 Long-term Equity Incentive Plan and the grant of options thereunder are intended to replace the Company’s 2021 Long-term Equity Incentive Plan and the share incentive awards granted thereunder, which were approved by the Company’s board of directors on November 3, 2021 and shareholders on December 28, 2021; and - To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
The board of directors of the Company has fixed the close of business on August 4, 2022 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company's Class A ordinary shares or Class B ordinary shares, each with a par value of US
The notice of the AGM and the Company’s 2021 Annual Report containing the complete audited financial statements and the report of auditors for the year ended December 31, 2021, is available on the Investor Relations Section of the Company’s website at https://ir.brbiotech.com/.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
When is Burning Rock Biotech's AGM scheduled?
What proposals will be discussed at the Burning Rock Biotech AGM?
What is the record date for shareholders to attend the Burning Rock AGM?
Where can I find the notice of the AGM for Burning Rock?
